Medtronic.gif” />

Medtronic has started enrolling patients in the STOP Persistent AF clinical trial of Arctic Front Advance cardiac cryoablation catheter for treatment of persistent atrial fibrillation (AF) in the US.

Equipped with the EvenCool Cryo technology, the Arctic Front Advance Cryoballoon is being developed to optimise delivery of coolant inside the balloon.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective, multi-centre, single-arm STOP Persistent AF trial is designed to assess the safety and effectiveness of a pulmonary vein isolation-only (PVI) strategy using the catheter.

To be conducted at 25 centres in the US, Canada, Europe and Japan, the trial will enroll approximately 225 patients.

It will include a follow up period of 12 months after the initial cryoballoon ablation procedure.

See Also:

Medtronic Cardiac and Vascular Group AF Solutions business vice-president and general manager Colleen Fowler said: "According to a study in JAMA, the number of patients with AF is expected to double in the next couple of decades and we want to ensure that physicians are equipped with the most innovative approaches and treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We hope this study leads to greater insights that can improve care for patients with persistent AF."

"We hope this study leads to greater insights that can improve care for patients with persistent AF."

According to the trial's co-principal investigator Hugh Calkins, results from the trial are expected to aid in determining the possible treatment options for persistent AF patients.

The firm's cardiac cryoablation system has been used in more than 250,000 cases.

In the US, the system is approved to treat drug-refractory, recurrent, symptomatic paroxysmal AF and in Europe for the treatment of AF.

Image: Illustration of the Arctic Front Advance Cryoballoon placed in the pulmonary vein. Photo: courtesy of Medtronic.